RHB-107 - COVID-19

RHB 107

RHB-107, an investigation drug, is a proprietary, first-in-class, novel orally-administered potent inhibitor of several serine proteases, with antiviral and potential tissue-protective effects.

RHB-107 has demonstrated strong inhibition of SARS-CoV-2 viral replication in an in vitro human bronchial epithelial cell model.

Serine proteases are involved in preparing the viral spike protein for viral entry into target cells. Because its mechanism of action is host-cell targeted, RHB-107 is expected to also be effective against emerging viral variants with mutations in the spike protein.

RHB-107 has a strong clinical safety and biodistribution profile, demonstrated in previous clinical studies, including several Phase 1 and Phase 2 studies in different indications, in approximately 200 patients.

RHB-107 is being evaluated in an ongoing Phase 2/3 study in the U.S. and South Africa for the treatment of non-hospitalized patients with symptomatic COVID-19 early in the course of the disease, who do not require supplemental oxygen. The study is a 2-part, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that aims to enroll up to 310 patients.

The Phase 2/3 clinical study with RHB-107 in COVID-19 is registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.